Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation

被引:75
作者
Gan, Tong J. [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA
关键词
D O I
10.2165/00003088-200645090-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The ability to deliver safe and effective moderate sedation is crucial to the ability to perform invasive procedures. Sedative drugs should have a quick onset of action, provide rapid and clear-headed recovery, and be easy to administer and monitor. A number of drugs have been demonstrated to provide effective sedation for outpatient procedures but since each agent has its own limitations, a thorough knowledge of the available drugs is required to choose the appropriate drug, dose and/or combination regimen for individual patients. Midazolam, propofol, ketamine and sevoflurane are the most frequently used agents, and all have a quick onset of action and rapid recovery. The primary drawback of midazolam is the potential for accumulation of the drug, which can result in prolonged sedation and a hangover effect. The anaesthetics propofol and sevoflurane have recently been used for sedation in procedures of short duration. Although effective, these agents require monitored anaesthesia care. Ketamine is an effective agent, particularly in children, but there is concern regarding emergence reactions. AQUAVAN (R) injection (fospropofol disodium), a phosphorylated prodrug of propofol, is an investigational agent possessing a unique and distinct pharmacokinetic and pharmacodynamic profile. Compared with propofol emulsion, AQUAVAN (R) is associated with a slightly longer time to peak effect and a more prolonged pharmacodynamic effect. Advances in the delivery of sedation, including the development of new sedative agents, have the potential to further improve the provision of moderate sedation for a variety of invasive procedures.
引用
收藏
页码:855 / 869
页数:15
相关论文
共 103 条
[1]   Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil [J].
Abi-Dargham, A ;
Krystal, JH ;
Anjilvel, S ;
Scanley, BE ;
Zoghbi, S ;
Baldwin, RM ;
Rajeevan, N ;
Ellis, S ;
Petrakis, IL ;
Seibyl, JP ;
Charney, DS ;
Laruelle, M ;
Innis, RB .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (11) :1550-1555
[2]   The effect of age on the pharmacokinetics and pharmacodynamics of midazolam [J].
Albrecht, S ;
Ihmsen, H ;
Hering, W ;
Geisslinger, G ;
Dingemanse, J ;
Schwilden, H ;
Schüttler, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (06) :630-639
[3]  
*AM SOC AN, 2005, ANESTHESIOLOGY, V96, P1004
[4]   The use of a ketamine-propofol combination during monitored anesthesia care [J].
Badrinath, S ;
Avramov, MN ;
Shadrick, M ;
Witt, TR ;
Ivankovich, AD .
ANESTHESIA AND ANALGESIA, 2000, 90 (04) :858-862
[5]   Procedural sedation and analgesia: A review and new concepts [J].
Bahn, EL ;
Holt, KR .
EMERGENCY MEDICINE CLINICS OF NORTH AMERICA, 2005, 23 (02) :503-+
[6]   PROLONGED SEDATION DUE TO ACCUMULATION OF CONJUGATED METABOLITES OF MIDAZOLAM [J].
BAUER, TM ;
RITZ, R ;
HABERTHUR, C ;
HA, HR ;
HUNKELER, W ;
SLEIGHT, AJ ;
SCOLLOLAVIZZARI, G ;
HAEFELI, WE .
LANCET, 1995, 346 (8968) :145-147
[7]   Clinical pharmacokinetics of sevoflurane [J].
Behne, M ;
Wilke, HJ ;
Harder, S .
CLINICAL PHARMACOKINETICS, 1999, 36 (01) :13-26
[8]   INTRAVENOUS MIDAZOLAM FOR UPPER GASTROINTESTINAL ENDOSCOPY - A STUDY OF 800 CONSECUTIVE CASES RELATING DOSE TO AGE AND SEX OF PATIENT [J].
BELL, GD ;
SPICKETT, GP ;
REEVE, PA ;
MORDEN, A ;
LOGAN, RFA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 23 (02) :241-243
[9]   Dexmedetomidine [J].
Bhana, N ;
Goa, KL ;
McClellan, KJ .
DRUGS, 2000, 59 (02) :263-268
[10]  
BLOOM JW, 1992, CLIN THER, V14, P895